Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)

Fig. 1

pCR ratesa in HER2 biomarker subgroups. A HER2 IHC staining percentage; B HER2/CEP17 gene ratio and HER2 mRNA level; C the pattern of HER2 stainingb; and D PIK3CA status. aAll unevaluable patients or patients with missing response data were considered to be nonresponders (TCH + P, n = 7 [3.2%]; T-DM1 + P, n = 18 [8.1%]). bCategorization based on sum of IHC2+ and IHC3+ staining percentages. cIncludes two patients with HER2-negative BC. BC breast cancer, CI confidence interval, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, mRNA messenger RNA, NE not evaluable, pCR pathologic complete response, PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, TCH + P docetaxel, carboplatin, and trastuzumab plus pertuzumab, T-DM1 + P trastuzumab emtansine plus pertuzumab

Back to article page